CERTAIN CONFIDENTIAL INFORMATION (MARKED BY BRACKETS AS “[*confidential
treatment requested*]”) HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH
(I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.

Exhibit 10.1

Amendment No. 17 to the License Agreement

This Amendment No. 17 ("Amendment No. 17"), effective as of August 1, 2020,
("Amendment Effective Date") to the License Agreement dated as of November 1,
1994, by and between S&P Dow Jones Indices, LLC ("S&P")  and Cboe Exchange, Inc.
("CBOE"), as previously amended by Amendment No. 1 effective January 15, 1995,
Amendment No. 2 effective April 1, 1998, Amendment No. 3 effective July 28,
2000, Amendment No. 4 effective October 27, 2000, Amendment No. 5 effective
March 1, 2003, Amended and Restated Amendment No. 6 effective February 24, 2009
(which implemented "Addendum No. 1"), Amended and Restated Amendment No. 7
effective February 24, 2009, Amendment No. 8 effective January 9, 2005,
Amendment No. 10 effective June 19, 2009, Amendment No. 11 effective April 29,
2010, Amendment No. 12 effective March 8, 2013, Amendment No. 13 effective
December 21, 2017, Amendment No. 14 effective  January 1, 2017, Amendment No. 15
effective January 15, 2019, and Amendment No. 16 effective April 1, 2020
(Amendment No. 9 effective April 23, 2007 having been terminated as of February
24, 2009), (the License Agreement, as so amended, the "Prior Agreement"). This
Amendment No. 17 and the Prior Agreement shall hereafter be known as the
"Agreement".

WHEREAS, Cboe and S&P desire to establish a reduced fee to be paid to S&P in
connection with trading on Cboe’s Markets of Mini-VIX Contracts (as defined
below).

NOW THEREFORE, the parties agree as follows:

1.New paragraph (z) is added to Section 1 of Addendum No. 1 to the Prior
Agreement, as follows:

(z)“Mini-VIX Contract” means a Category I Product or Category II Product based
on the Cboe Volatility Index (a/k/a the “VIX Index”) that has a notional value
that is less than [*confidential treatment requested*] percent ([*confidential
treatment requested*]%) of the notional value of the corresponding standard size
Product.

2.Exhibit C to Addendum No. 1 of the Prior Agreement is hereby deleted and
replaced in its entirety with amended and restated Exhibit C, attached hereto.
3.Terms that are used in this Amendment No. 17 with reference to the Prior
Agreement but not modified or otherwise redefined herein shall have the
respective meanings set forth in the Prior Agreement.  Provisions of the Prior
Agreement not expressly modified by this Amendment No. 17 will continue in
effect.

The terms and conditions of this Amendment No. 17 are acknowledged and agreed
to:

Cboe Exchange, Inc.

S&P Dow Jones Indices, LLC

Signature:

/s/ John F. Deters                                

Signature:

/s/ Jamie Farmer

Name:

John F. Deters

Name:

Jamie Farmer

Title:

EVP, CSO

Title:

Chief Commercial Officer

Date:

August 1, 2020

Date:

September 21, 2020

--------------------------------------------------------------------------------

CERTAIN CONFIDENTIAL INFORMATION (MARKED BY BRACKETS AS “[*confidential
treatment requested*]”) HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH
(I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.

EXHIBIT C

(to Addendum No. 1)

FEES

1.Pursuant to Section 6(a) of this Addendum No. 1, CBOE shall pay fees to S&P
computed as follows:

(1)For Category I Products and Category II Products based on any BuyWrite Index
or a Volatility Index, other than a Mini-VIX Contract, a fee of $[*confidential
treatment requested*] per Contract

(2)For Category I Products and Category II Products based on any Variance
Indicator, a fee of: $[*confidential treatment requested*] per Contract during
calendar year 2013; $[*confidential treatment requested*] per Contract during
calendar year 2014; $[*confidential treatment requested*] per Contract during
calendar years 2015-2022; and $[*confidential treatment requested*] per Contract
during the remaining term of this Agreement

(3)For Mini-VIX Contracts, a fee of $[*confidential treatment requested*] per
Contract

(4)[*confidential treatment requested*] percent ([*confidential treatment
requested*]%) of all revenues received by CBOE, excluding sales, value-added and
similar taxes, in connection with the license from CBOE to Rampart pursuant to
the arrangement described in Section 2(f).

Notwithstanding the foregoing or any other provision of this Agreement:

(A)During any Volatility Index Non-exclusive Period (x) CBOE shall not be
obligated to pay any fees with respect to Contracts on the Volatility Index
subject to the Volatility Index Non-exclusive Period until such time during the
term of the Agreement, if ever, as the Volatility Index Non-exclusive Period is
no longer in effect for such Volatility Index, and (y) CBOE shall have no
obligation to make any payment to S&P determined in accordance with Addendum No.
3. If CBOE is successful in causing the Volatility Index Non-exclusivity Period
no longer to be in effect during the term of the Agreement, CBOE shall promptly
pay S&P an amount equal to the fees that CBOE did not pay pursuant to the
foregoing sentence, reduced by an amount (but not to less than zero) equal to
the costs incurred by CBOE to cause the Volatility Index Non-exclusive Period no
longer to be in effect.

(B)If another Market (as defined below) provides a market for the trading of any
Category I or Category II Product based on any BuyWrite Index or Variance
Indicator without having been granted a license to do so by S&P with the consent
of CBOE, CBOE shall have no obligation to pay any per-contract fee with respect
to such Product during the time that such other Market is providing such a
market.

The term “Market” as used in the preceding sentence is used to mean any
regulated exchange or contract market, automated quotation system, electronic
communications network or other similar market system.

2.Pursuant to Section 6(b) of this Addendum No. 1, S&P shall pay fees to CBOE
computed as follows:

[*confidential treatment requested*] percent ([*confidential treatment
requested*]%) of all revenues, excluding sales, value-added and similar taxes,
received by S&P in connection with

--------------------------------------------------------------------------------

CERTAIN CONFIDENTIAL INFORMATION (MARKED BY BRACKETS AS “[*confidential
treatment requested*]”) HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH
(I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.

licenses granted by S&P to third parties that issue, sell, sponsor, distribute,
market and/or promote Products based on the Amendment No. 6 Indexes, as
contemplated under Section 3.

The parties acknowledge and agree that the Fee Schedule set forth in this
Exhibit C shall have effect from and after August 1, 2020.

The parties agree that the terms upon which License Fees are calculated pursuant
to this Exhibit C shall be considered confidential information of each party for
purposes of Subsection 11(b) of the License Agreement.

--------------------------------------------------------------------------------